JP6358953B2 - タウを認識するホスホ特異的抗体 - Google Patents

タウを認識するホスホ特異的抗体 Download PDF

Info

Publication number
JP6358953B2
JP6358953B2 JP2014533928A JP2014533928A JP6358953B2 JP 6358953 B2 JP6358953 B2 JP 6358953B2 JP 2014533928 A JP2014533928 A JP 2014533928A JP 2014533928 A JP2014533928 A JP 2014533928A JP 6358953 B2 JP6358953 B2 JP 6358953B2
Authority
JP
Japan
Prior art keywords
antibody
tau
seq
amino acid
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014533928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531216A (ja
Inventor
アンドレア ファイファー，
アンドレア ファイファー，
アンドレアス ムース，
アンドレアス ムース，
マリア ピルグレン，
マリア ピルグレン，
オスカル アドルフソン，
オスカル アドルフソン，
ルーヴェン， フレッド ヴァン
ルーヴェン， フレッド ヴァン
Original Assignee
エーシー イミューン エス．エー．
エーシー イミューン エス．エー．
カトリーケ ユニヴェルシテート ルーヴェン
カトリーケ ユニヴェルシテート ルーヴェン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/067604 external-priority patent/WO2012045882A2/en
Application filed by エーシー イミューン エス．エー．, エーシー イミューン エス．エー．, カトリーケ ユニヴェルシテート ルーヴェン, カトリーケ ユニヴェルシテート ルーヴェン filed Critical エーシー イミューン エス．エー．
Publication of JP2014531216A publication Critical patent/JP2014531216A/ja
Application granted granted Critical
Publication of JP6358953B2 publication Critical patent/JP6358953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
JP2014533928A 2011-10-07 2012-10-05 タウを認識するホスホ特異的抗体 Active JP6358953B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2011/067604 WO2012045882A2 (en) 2010-10-07 2011-10-07 Pharmaceutical composition
EPPCT/EP2011/067604 2011-10-07
EP12163319 2012-04-05
EP12163319.2 2012-04-05
PCT/EP2012/069783 WO2013050567A1 (en) 2011-10-07 2012-10-05 Phosphospecific antibodies recognising tau

Publications (2)

Publication Number Publication Date
JP2014531216A JP2014531216A (ja) 2014-11-27
JP6358953B2 true JP6358953B2 (ja) 2018-07-18

Family

ID=48043196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533928A Active JP6358953B2 (ja) 2011-10-07 2012-10-05 タウを認識するホスホ特異的抗体

Country Status (12)

Country Link
US (2) US9540434B2 (enExample)
EP (2) EP2764022B9 (enExample)
JP (1) JP6358953B2 (enExample)
KR (1) KR101981351B1 (enExample)
CN (2) CN104080806B (enExample)
AR (1) AR092779A1 (enExample)
BR (2) BR112014008202B1 (enExample)
CA (1) CA2850686C (enExample)
ES (1) ES2600915T3 (enExample)
MX (1) MX354662B (enExample)
RU (1) RU2639537C2 (enExample)
WO (1) WO2013050567A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014008202B1 (pt) 2011-10-07 2022-01-04 Ac Immune S.A. Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção da formação de um complexo imunológico, método de detecção post­mortem de multimêros do fosfo-tau, kits de teste, linhagem celular isolada e método de detecção de multimêros de fosfo-tau
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
MY171473A (en) 2012-07-03 2019-10-15 Univ Washington Antibodies to tau
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
GB201319656D0 (en) * 2013-11-07 2013-12-25 Univ Leuven Kath A yeast model for synergistic toxicity
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
SG11201610446XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016007414A1 (en) * 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN108137679B (zh) * 2015-08-13 2022-07-19 纽约大学 对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
SG11201808434WA (en) * 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
GEP20217222B (en) 2016-07-12 2021-02-10 Lundbeck A/S H Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
MY198942A (en) 2016-12-07 2023-10-03 Genentech Inc Anti-tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
WO2018127519A1 (en) * 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
JP7362636B2 (ja) * 2018-03-05 2023-10-17 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｐｈｆ－タウ抗体及びその使用
CA3090356A1 (en) * 2018-03-11 2019-09-19 Koorosh Shahpasand Conformation-independent antibodies against neurotoxic tau proteins
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
AU2019262220B2 (en) * 2018-05-03 2025-10-16 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
US12016885B2 (en) 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN113748343A (zh) * 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
US12493043B2 (en) 2019-09-10 2025-12-09 Washington University Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
EP4252243A2 (en) 2020-11-30 2023-10-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
TW202239765A (zh) * 2020-12-16 2022-10-16 美商航海家醫療公司 Tau結合化合物
CN112694532B (zh) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 抗Siglec-15的抗体或其抗原结合片段及应用
CN113533746B (zh) * 2021-07-22 2022-05-10 深圳市天大生物医疗器械有限公司 一种P-Tau蛋白化学发光检测试剂盒及其制备方法
KR20240067082A (ko) 2021-09-09 2024-05-16 알즈패스, 인크. 포스포-타우 항체 및 사용 방법
CN114002435A (zh) * 2021-10-13 2022-02-01 华中科技大学 三种用于检测人磷酸化Tau蛋白的试剂盒及其制备方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2024192404A1 (en) * 2023-03-16 2024-09-19 Alzpath, Inc. Methods of diagnosing and treating neurodegenerative disorders
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN117866087B (zh) * 2024-03-11 2024-05-17 江西赛基生物技术有限公司 一种抗pTau181单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1993003148A2 (en) * 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Tau/neurofilament protein kinases pk40 and pk36
DK0618968T3 (da) * 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
AU702436B2 (en) 1994-10-21 1999-02-18 Innogenetics N.V. New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
MXPA03000316A (es) 2000-07-11 2004-04-05 Molecular Geriatrics Corp Reactivos y metodos para la identificacion de agentes de enlace.
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
EA012325B1 (ru) 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
UA102368C2 (ru) * 2005-12-12 2013-07-10 Ас Иммуне С.А. СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008050383A1 (fr) * 2006-10-23 2008-05-02 Pioneer Corporation Dispositif de reproduction vidéo, système d'affichage vidéo et support d'enregistrement
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
CA2692039C (en) 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
ES2445590T3 (es) * 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
AU2008312802A1 (en) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to abeta oligomer, and use thereof
PT2408807T (pt) * 2009-03-18 2021-09-03 Ac Immune Sa Processo para utilização terapêutica
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8748386B2 (en) * 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
CN102070718A (zh) 2010-03-23 2011-05-25 中国疾病预防控制中心病毒病预防控制所 人tau蛋白外显子2、外显子3、外显子10多克隆抗体
HUE027649T2 (en) * 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
BR112014008202B1 (pt) 2011-10-07 2022-01-04 Ac Immune S.A. Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção da formação de um complexo imunológico, método de detecção post­mortem de multimêros do fosfo-tau, kits de teste, linhagem celular isolada e método de detecção de multimêros de fosfo-tau
KR102132041B1 (ko) * 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
US20150133310A1 (en) 2012-05-02 2015-05-14 Ibis Biosciences, Inc. Nucleic acid sequencing systems and methods

Also Published As

Publication number Publication date
BR112014008202B1 (pt) 2022-01-04
CA2850686C (en) 2020-09-08
RU2014118456A (ru) 2015-11-20
EP2764022A1 (en) 2014-08-13
JP2014531216A (ja) 2014-11-27
EP3135689A1 (en) 2017-03-01
ES2600915T3 (es) 2017-02-13
EP3135689B1 (en) 2018-12-19
BR112014008202A2 (enExample) 2017-08-15
US10066010B2 (en) 2018-09-04
EP2764022B9 (en) 2017-02-22
BR122021017560B1 (pt) 2023-03-07
US9540434B2 (en) 2017-01-10
US20140294731A1 (en) 2014-10-02
MX354662B (es) 2018-03-14
CN108034005B (zh) 2021-06-25
CN108034005A (zh) 2018-05-15
RU2639537C2 (ru) 2017-12-21
KR20140070658A (ko) 2014-06-10
US20170137502A1 (en) 2017-05-18
WO2013050567A1 (en) 2013-04-11
CA2850686A1 (en) 2013-04-11
CN104080806A (zh) 2014-10-01
KR101981351B1 (ko) 2019-09-02
AR092779A1 (es) 2015-05-06
MX2014004026A (es) 2014-08-27
CN104080806B (zh) 2018-01-19
EP2764022B1 (en) 2016-08-17
HK1200469A1 (en) 2015-08-07

Similar Documents

Publication Publication Date Title
JP6358953B2 (ja) タウを認識するホスホ特異的抗体
US10100104B2 (en) Methods of diagnosing tau-protein-associated disease
JP6293731B2 (ja) ヒト化タウ抗体
AU2013205313A1 (en) Phosphospecific antibodies recognising tau
HK1200469B (en) Phosphospecific antibodies recognising tau
TW201321409A (zh) 醫藥組合物
HK1187928B (en) Antibodies recognising phospho-tau

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180522

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180619

R150 Certificate of patent or registration of utility model

Ref document number: 6358953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250